SOLIGENIX, INC.

SNGX · Nasdaq · SIC 2834: Pharmaceutical Preparations
336
SEC Filings

Business Summary

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases with unmet medical needs. It operates two segments: Specialized BioTherapeutics (HyBryte for CTCL, SGX302 for psoriasis, dusquetide for Behcet's Disease and oral mucositis) and Public Health Solutions (RiVax ricin vaccine, SGX943 for infectious disease, filovirus vaccines, CiVax for COVID-19), leveraging its proprietary ThermoVax heat stabilization platform with government funding support.

Next Earnings

Q2 FY2026 — expected 2026-09-19

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionSNGXdiscussed_in_filing Cybersecurity
topic_mentionSNGXdiscussed_in_filing Trusted Computing
topic_mentionSNGXdiscussed_in_filing Blockchain & Crypto
topic_mentionSNGXdiscussed_in_filing Regulation
topic_mentionSNGXdiscussed_in_filing Healthcare & Bio
topic_mentionSNGXdiscussed_in_filing Platform & Ecosystem
topic_mentionSNGXdiscussed_in_filing Sovereign & Government
topic_mentionSNGXdiscussed_in_filing Cybersecurity
topic_mentionSNGXdiscussed_in_filing Trusted Computing
topic_mentionSNGXdiscussed_in_filing Blockchain & Crypto
topic_mentionSNGXdiscussed_in_filing Regulation
topic_mentionSNGXdiscussed_in_filing Healthcare & Bio
topic_mentionSNGXdiscussed_in_filing Platform & Ecosystem
topic_mentionSNGXdiscussed_in_filing Sovereign & Government
topic_mentionSNGXdiscussed_in_filing Cybersecurity
topic_mentionSNGXdiscussed_in_filing Trusted Computing
topic_mentionSNGXdiscussed_in_filing Blockchain & Crypto
topic_mentionSNGXdiscussed_in_filing Regulation
topic_mentionSNGXdiscussed_in_filing Healthcare & Bio
topic_mentionSNGXdiscussed_in_filing Platform & Ecosystem

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-312025-12-310001104659-26-037701EDGAR75K words
2025-03-212024-12-310001558370-25-003459EDGAR—
2024-03-152023-12-310001558370-24-003402EDGAR—
2023-03-312022-12-310001558370-23-005304EDGAR—
2022-03-292021-12-310001558370-22-004605EDGAR—
2021-03-302020-12-310001213900-21-018698EDGAR—
2020-03-302019-12-310001213900-20-007959EDGAR—
2019-03-262018-12-310001213900-19-004865EDGAR—
2018-03-152017-12-310001213900-18-003007EDGAR—
2017-03-272016-12-310001213900-17-002845EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-072025-09-300001104659-25-108475EDGAR30K words
2025-08-142025-06-300001558370-25-011554EDGAR—
2025-05-092025-03-310001558370-25-007171EDGAR—
2024-11-082024-09-300001558370-24-015054EDGAR—
2024-08-092024-06-300001558370-24-011740EDGAR—
2024-05-102024-03-310001558370-24-007782EDGAR—
2023-11-132023-09-300001558370-23-018818EDGAR—
2023-08-212023-06-300001558370-23-015144EDGAR—
2023-05-152023-03-310001558370-23-009929EDGAR—
2022-11-102022-09-300001558370-22-017406EDGAR—
2022-08-122022-06-300001558370-22-013491EDGAR—
2022-05-132022-03-310001558370-22-008747EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-02-120001104659-26-014267EDGAR1K words
2026-01-230001104659-26-006233EDGAR—
2025-11-180001104659-25-113645EDGAR—
2025-09-290001104659-25-094507EDGAR—
2025-08-180001558370-25-011625EDGAR—
2025-08-150001558370-25-011619EDGAR—
2025-07-310001104659-25-072708EDGAR—
2025-06-200001558370-25-008772EDGAR—
2025-03-280001558370-25-003987EDGAR—
2025-02-100001558370-25-000726EDGAR—

336 total filings indexed. 304 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

rare-diseases cutaneous-t-cell-lymphoma psoriasis infectious-diseases-and-biodefense oncology-supportive-care public-health-vaccines photodynamic-therapy-(pdt)-using-visible-fluorescent-light innate-defense-regulator-(idr)-technology thermovax-heat-stabilization-platform cails-(composite-assessment-of-index-lesion-disease-severity)-scoring

Company Identity

CIK0000812796
TickerSNGX
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE
HeadquartersPrinceton, New Jersey

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: a18a947f3f3dc86e76b71b07dfda35ace4dec8976bade159f32d2336838fe404
parent: 7b70cc2c317ce2849296b4bbde25c2824f63ce762815de8b72ac72e5d2f3d8a0
content hash: 96f538e29621987c2eb5b96d2509d1c2f930517e7281cc437b75bbe689bd0408
signed: 2026-04-13T04:47:31.327Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf